中医药防治肿瘤相关性贫血的优势与特色

Advantages and characteristics of traditional Chinese medicine in the prevention and treatment of cancer-related anemia

肿瘤相关性贫血(CRA)是肿瘤发生发展及治疗过程中的常见并发症。作为肿瘤患者预后的独立危险因素,CRA总体发生率约30%~90%,严重影响了临床疗效、生活质量和生存预后。我国仅有7.16%的肿瘤患者获得了针对贫血的相关治疗,轻度贫血患者仅1.8%接受过相关治疗。当前CRA呈现发病率高、治疗率低、治疗效果一般的现状,及时有效地防治CRA对肿瘤患者至关重要。中医药防治CRA具有独特的优势和特色,在促进骨髓造血、提升血红蛋白水平的同时,防治结合,多靶点保护全血细胞,显著缓解患者全身症状,提高生活质量,并可降低相关不良事件的发生。

Cancer-related anemia(CRA) is a common complication in the development and treatment of tumors. As an independent risk factor for the prognosis of tumor patients, the overall incidence of CRA is approximately 30% to 90%, which seriously affects the clinical efficacy, quality of life, and survival prognosis. In China, only 7.16% of tumor patients have received treatment for anemia, and only 1.8% of those with mild anemia have received related treatment. At present, CRA has a high incidence rate, low treatment rate, and a general treatment effect. Timely and effective prevention and treatment of CRA is crucial for tumor patients. Traditional Chinese medicine has unique advantages and characteristics in the prevention and treatment of CRA, including promoting bone marrow hematopoiesis and improving hemoglobin levels, as well as combining prevention and treatment by protecting whole blood cells with multiple targets, significantly relieving systemic symptoms, improving quality of life, and reducing the incidence of related adverse events.